The findings of this study suggest that betatrophin could be a favorable indicator that reflects body fat distribution during the normal stage of glucose intolerance and could be a simple and reliable risk assessment surrogate for CAD and metabolic disease in clinical practice. Here, ANGPTL8 is linked to Other metabolic disease.